EASO Update Gives Clearer Roles for Tirzepatide, Semaglutide
The European Association for the Study of Obesity has updated its pharmacotherapy framework, prioritizing tirzepatide over semaglutide for weight loss. The update emphasizes a patient-centered approach to obesity care, focusing on complications rather than just weight loss. It also introduces a treatment algorithm to help clinicians select medications based on individual patient needs and evidence from recent trials.
- ▪The updated framework places tirzepatide ahead of semaglutide for weight loss.
- ▪Both drugs are positioned for metabolic dysfunction-associated steatohepatitis resolution, with semaglutide alone recommended for liver fibrosis improvement.
- ▪The algorithm aims to match medications to patients' weight-loss goals and obesity-related complications.
Opening excerpt (first ~120 words) tap to expand
ISTANBUL — The European Association for the Study of Obesity (EASO) has updated its obesity pharmacotherapy framework, placing tirzepatide ahead of semaglutide for weight loss, while positioning both drugs for metabolic dysfunction-associated steatohepatitis (MASH) resolution and semaglutide alone for improvement in liver fibrosis.“We are moving beyond a simple focus on weight loss alone and toward a much more complication-focused and patient-centered approach to obesity care,” said Barbara McGowan, MD, professor of obesity medicine at Guy’s and St Thomas’ NHS Foundation Trust in London, England, presenting the update at a press briefing.The framework includes a treatment algorithm designed to help clinicians match medications to patients’ weight-loss goals and obesity-related…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Medscape.
Discussion
0 commentsMore from Medscape
